Free Trial

Entero Therapeutics (ENTO) Competitors

Entero Therapeutics logo
$0.39 -0.01 (-1.26%)
As of 11:03 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ENTO vs. PMCB, ORGS, CLDI, ARTL, APLM, CVM, SLXN, OMGA, CELZ, and AIM

Should you be buying Entero Therapeutics stock or one of its competitors? The main competitors of Entero Therapeutics include Nuvilex (PMCB), Orgenesis (ORGS), Calidi Biotherapeutics (CLDI), Artelo Biosciences (ARTL), Apollomics (APLM), CEL-SCI (CVM), Silexion Therapeutics (SLXN), Omega Therapeutics (OMGA), Creative Medical Technology (CELZ), and AIM ImmunoTech (AIM). These companies are all part of the "pharmaceutical products" industry.

Entero Therapeutics vs. Its Competitors

Nuvilex (NASDAQ:PMCB) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NuvilexN/AN/A$330K$0.741.53
Entero TherapeuticsN/AN/A-$18.06MN/AN/A

Nuvilex's return on equity of 0.51% beat Entero Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
NuvilexN/A 0.51% 0.35%
Entero Therapeutics N/A -1,063.82%-26.06%

Nuvilex has a beta of -0.42, suggesting that its stock price is 142% less volatile than the S&P 500. Comparatively, Entero Therapeutics has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500.

34.2% of Nuvilex shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 10.2% of Nuvilex shares are held by company insiders. Comparatively, 0.8% of Entero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Nuvilex's average media sentiment score of 0.00 equaled Entero Therapeutics'average media sentiment score.

Company Overall Sentiment
Nuvilex Neutral
Entero Therapeutics Neutral

Summary

Nuvilex beats Entero Therapeutics on 5 of the 6 factors compared between the two stocks.

Get Entero Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENTO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ENTO vs. The Competition

MetricEntero TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.90M$2.89B$5.48B$8.94B
Dividend YieldN/A2.44%5.24%4.05%
P/E RatioN/A20.6427.3120.15
Price / SalesN/A192.11372.7693.81
Price / CashN/A41.7026.2128.59
Price / Book-0.497.417.975.61
Net Income-$18.06M-$55.04M$3.17B$248.49M
7 Day Performance1.92%4.08%2.72%6.17%
1 Month Performance-23.46%1.24%2.15%7.89%
1 Year Performance-61.73%4.56%33.95%21.19%

Entero Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ENTO
Entero Therapeutics
N/A$0.40
+0.3%
N/A-62.9%$1.90MN/A0.009
PMCB
Nuvilex
0.8957 of 5 stars
$1.14
+4.6%
N/A-47.4%$7.48MN/A1.544Positive News
High Trading Volume
ORGS
Orgenesis
N/A$1.53
+3.7%
N/AN/A$7.34M$662K0.00150Gap Down
CLDI
Calidi Biotherapeutics
0.3429 of 5 stars
$0.23
flat
N/A-87.9%$7.31M$50K0.0038News Coverage
ARTL
Artelo Biosciences
2.9632 of 5 stars
$9.50
-28.4%
$33.00
+247.4%
+78.8%$7.26MN/A-0.535News Coverage
Analyst Upgrade
Gap Up
High Trading Volume
APLM
Apollomics
0.3398 of 5 stars
$6.38
-2.8%
N/A-66.3%$7.24M$1.49M0.0045Positive News
CVM
CEL-SCI
0.0808 of 5 stars
$2.37
+3.5%
N/A-93.7%$7.19MN/A-4.9443News Coverage
SLXN
Silexion Therapeutics
N/A$0.80
-1.0%
$5.00
+523.2%
N/A$7.04MN/A0.00N/A
OMGA
Omega Therapeutics
2.1075 of 5 stars
$0.13
-21.8%
$8.50
+6,700.0%
-93.0%$6.92M$8.10M-0.09120Gap Up
CELZ
Creative Medical Technology
N/A$2.64
-0.4%
N/A-30.4%$6.85M$10K-0.695Positive News
AIM
AIM ImmunoTech
1.6679 of 5 stars
$8.93
+3.2%
$275.00
+2,981.2%
-76.6%$6.82M$146K-18.9920

Related Companies and Tools


This page (NASDAQ:ENTO) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners